These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33889015)

  • 21. Prevalence and associated metabolic factors of fatty liver disease in the elderly.
    Wang Z; Xu M; Peng J; Jiang L; Hu Z; Wang H; Zhou S; Zhou R; Hultström M; Lai EY
    Exp Gerontol; 2013 Aug; 48(8):705-9. PubMed ID: 23721951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings.
    Khosravi S; Alavian SM; Zare A; Daryani NE; Fereshtehnejad SM; Daryani NE; Keramati MR; Abdollahzade S; Taba Taba Vakili S
    Hepat Mon; 2011 Jun; 11(6):452-8. PubMed ID: 22087177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
    Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
    Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening of Family Members of Nonalcoholic Fatty Liver Disease Patients can Detect Undiagnosed Nonalcoholic Fatty Liver Disease Among Them: Is There a Genetic Link?
    Jain S; Thanage R; Panchal F; Rathi PM; Munshi R; Udgirkar SS; Contractor QQ; Chandnani SJ; Sujit NP; Debnath P; Singh A
    J Clin Exp Hepatol; 2021; 11(4):466-474. PubMed ID: 34276153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
    World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
    Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.
    Wong VW; Vergniol J; Wong GL; Foucher J; Chan HL; Le Bail B; Choi PC; Kowo M; Chan AW; Merrouche W; Sung JJ; de Lédinghen V
    Hepatology; 2010 Feb; 51(2):454-62. PubMed ID: 20101745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
    Elkabany ZA; Hamza RT; Ismail EAR; Elsharkawy A; Yosry A; Musa S; Khalaf MA; Elgawesh RM; Esmat G
    Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):1008-1016. PubMed ID: 31834057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?
    McPherson S; Anstee QM; Henderson E; Day CP; Burt AD
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):652-8. PubMed ID: 23325287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease.
    Chhatwal J; Dalgic OO; Chen W; Samur S; Bethea ED; Xiao J; Hur C; Corey KE; Loomba R
    JAMA Netw Open; 2022 Sep; 5(9):e2230426. PubMed ID: 36098969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the dietary factors associated with suspected pediatric nonalcoholic fatty liver disease and potential liver fibrosis: Korean National Health and Nutrition Examination Survey 2014-2017.
    Kim MJ; Lee KJ
    BMC Pediatr; 2020 Mar; 20(1):121. PubMed ID: 32171275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience.
    Rath MM; Panigrahi MK; Pattnaik K; Bhuyan P; Kar SK; Misra B; Misra D; Meher C; Agrawal O; Rath J; Singh SP
    J Clin Exp Hepatol; 2016 Dec; 6(4):291-296. PubMed ID: 28003718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.